Glossary of terms

Most of the terms below appear in this online guide.

Advanced prostate cancerProstate cancer that has spread outside the prostate gland and pelvic lymph nodes to other places in the body like the bones, liver, or lungs. See metastasis.
Ashkenazi JewishSomeone with Jewish ancestors from Eastern Europe. In some cases, Ashkenazi Jewish ancestry is linked to an increased risk for certain cancers and may be a reason for germline genetic testing in some situations.
Biomarker testingAnother term for tumor testing or somatic testing. These terms all mean the same thing.
Biopsy specimenA sample of tissue used to diagnose or understand features of certain diseases, including cancer.
BRCA2 and BRCA1Two of the genes that help cells repair damaged DNA. Changes in these genes can raise the risk of certain cancers. For patients with advanced prostate cancer, changes in BRCA2 and BRCA1 genes may mean that targeted therapy with a PARP inhibitor is a treatment option.
CapivasertibAn oral cancer medicine approved for patients with metastatic androgen pathway modulator-naïve or sensitive (mAPMN/S) prostate cancer that is PTEN-deficient, as shown by an FDA-authorized test. Capivasertib is given in combination with abiraterone and prednisone. mAPMN/S prostate cancer is also known as metastatic hormone-sensitive prostate cancer (mHSPC).
Circulating tumor DNA (ctDNA)DNA released by tumor cells into the bloodstream. Testing of ctDNA uses a blood sample and does not require a biopsy.
DDR geneDDR means DNA damage repair. DDR genes help cells find and repair DNA damage. Changes in DDR genes can affect how cancer grows and how it responds to some treatments. Some DDR gene changes are linked to a higher risk of aggressive prostate cancer. You may also see the term HRR genes. HRR genes are one type of DDR gene. HRR genes include BRCA1, BRCA2, ATM, PALB2, and others.
DNAThe genetic code that tells your body how to grow, look, and work. Every cell in your body has a copy of your DNA, except your red blood cells.
FDA-authorizedApproved by the U.S. Food and Drug Administration to evaluate, diagnose, or treat a specific health condition.
GeneA small section of DNA that tells your body how to grow, look, or work. Humans have about 20,000 different genes.
Gene alterationA change in the DNA of a gene. You may be born with a gene alteration or it may happen during your lifetime. Some gene alterations can raise the risk of cancer or other diseases. Gene alterations are also called gene changes, gene variants, or mutations.
Genetic counselorA healthcare professional specially trained to help people understand genetic test results and decide whether to get tested.
Germline genetic testingA blood or saliva test that looks for gene changes passed down in some families. Some of these changes can raise the risk of cancer. Having one does not mean you have or will get cancer, but it can increase your risk. If you have prostate cancer, germline testing can help you and your doctor learn if certain treatments may work for you. It can also show if your blood relatives, both men and women, may have a higher risk of cancer. If so, they can take steps to protect their health, such as getting germline testing themselves or starting cancer screenings earlier.
Genomic testingAnother term for somatic testing. ‘Genomic’ comes from ‘genome,’ or the complete set of DNA in your body. Every person has a unique genome, and so does every tumor. Genomic testing helps show how your cancer may grow and change and which treatments may work well. It is done on a small piece of tumor tissue or a blood sample.
HereditaryPassed down from a parent to a child. In cancer medicine, the term ‘hereditary’ means that some gene alterations that are linked to cancer run in some families. If a parent has one of these gene alterations, there is a chance their child will be born with it, too.
Homologous recombination repair (HRR) genesA group of genes that help repair serious damage to DNA. They include BRCA1, BRCA2, ATM, CHEK2, PALB2, and others. An alteration (change) in an HRR gene may increase your risk of certain cancers, including prostate cancer. It may also mean that cancer is more likely to grow and spread if it develops. In some cases, it means that treatments such as PARP inhibitors may be a good option. HRR gene alterations can be inherited from a parent and found in all the cells of your body (germline), or they can develop only in cancer cells (somatic). This is why both germline and somatic testing are important to check for these gene changes.
Hormone therapyTreatments that lower the body’s level of male hormones like testosterone or stop it from fueling the growth of prostate cancer cells.
IHCThe abbreviation for immunohistochemistry.
ImmunotherapyA type of treatment that helps your body’s immune system find and fight cancer (tumor) cells.
Inherited cancer risk gene alterationsGene changes some people are born with that can raise their risk of getting one or more cancers. Found by testing blood or saliva.
Intraductal/cribriform histologyA form of prostate cancer in which the cancer cells grow in the ducts, or tiny tubes, inside the prostate gland.
Localized prostate cancerCancer that has not spread outside the prostate gland.
mCRPCProstate cancer that has spread and is no longer sensitive to hormone therapy.
MetastasisThe spread of cancer cells to another place in the body, where they form a new tumor. Cancer cells can spread through the blood or lymph fluid. Prostate cancer most often spreads to the lymph nodes or bones, but it can also spread to the liver, lungs, or other organs.
Metastatic prostate cancerProstate cancer that metastasized, or spread to distant parts of the body like the bones, lymph nodes, or organs. See advanced prostate cancer.
Metastatic hormone-sensitive prostate cancer (mHSPC)Prostate cancer that has spread to distant parts of the body but can still be controlled with hormone therapy. mHSPC is also called mAPMN/S prostate cancer—metastatic androgen pathway modulator-naïve or sensitive.
High tumor mutational burden (TMB-H)A tumor that has many changes (alterations) in its DNA. These cancers may respond well to certain immunotherapy treatments.
Microsatellite instability-high (MSI-H)A tumor that has a hard time repairing mistakes in its DNA. These tumors may respond well to certain immunotherapy treatments.
Mismatch repair deficiency (dMMR)When cells cannot properly fix mistakes that can happen when they copy their DNA. If DNA mistakes build up, it can lead to microsatellite instability-high (MSI-high).
MutationA gene change that can increase the risk of cancer or other diseases. Also called gene alteration.
Node-positive prostate cancerProstate cancer that has spread from the prostate gland to nearby lymph nodes, but not to other parts of the body.
PARP inhibitorPARP, or poly (ADP-ribose) polymerase, is a type of protein in the body. PARP inhibitors block PARP proteins, making it harder for cancer cells to repair their DNA and survive. A PARP inhibitor may be an option for advanced prostate cancer if genetic testing finds certain gene changes, such as BRCA2 or BRCA1 alterations. Examples of PARP inhibitors include olaparib, talazoparib, niraparib, and rucaparib. When you take a PARP inhibitor, testosterone-lowering treatment usually continues. Some PARP inhibitors are also taken with another hormone therapy medicine.
PTENStands for phosphatase and tensin homolog, a protein that helps block cancer growth signals. When PTEN is lacking, tumors may grow more quickly. PTEN deficiency means a lack of this protein in the tumor. Your doctor may also call this PTEN loss.
PTEN deficiency (PTEN loss)One of the most common changes found in prostate cancer. When prostate cancer lacks PTEN protein, it may grow and spread faster, come back after treatment, and respond less well to standard treatment. For some people with advanced prostate cancer and PTEN loss, a targeted treatment such as capivasertib may be an option. Your doctor can check for PTEN loss by ordering an FDA-authorized lab test called IHC.
PTEN testingChecks a tumor sample for PTEN deficiency, also known as PTEN loss. If prostate cancer has recently spread (metastasized), is still sensitive to hormone therapy, and has PTEN loss based on an FDA-authorized test, your doctor may recommend capivasertib with abiraterone and prednisone as a treatment option.
Somatic testingLooks for changes in your tumor DNA and proteins that help guide treatment selection. These changes occur in the tumor during your lifetime and are not inherited. Also known as biomarker or genomic testing.
VariantSee gene alteration.
Very high-risk or high-risk localized prostate cancerProstate cancer that has not spread outside the prostate gland but has characteristics that make spread much more likely.